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Translational Pancreatology. New Approaches in the Development of Novel 
Biomarkers as Screening Methodologies for Pancreatic Cancer.
Maria I Vaccaro*Roxana Resnik Institute of Biochemistry and Molecular Medicine (CONICET), School of Pharmacy and Bio-chemistry, University of Buenos Aires, Argentina
AbstractPancreatic Ductal Adenocarcinoma (PDAC) is one of the rare cancers for which no 
significant improvements in diagnosis and therapy have been made in the last 30 years. 
Despite considerable progress the median survival of most patients is 5 to 6 months. 
Currently, 80% of patients diagnosed with pancreatic adenocarcinoma present with locally 
invasive and/or metastatic disease, resulting in a poor 5-year survival of <5%. Hence, 
less than 20% of patients with PDAC undergo potentially curative surgery, whereas the 
remaining patients, can only be offered palliative treatment. Only 15–20% of patients 
undergo resection.
The development of a diagnostic tool for early detection of patients with this malignancy 
may significantly impact their prognosis. Pancreatic cancer has a strong correlation 
between tumor stage and prognosis. The size of the tumors is also important in a general sense, the smaller ones have metastases less frequently than the larger ones at the time 
of diagnosis and, therefore, are more likely to be cured by surgery. Therefore, it is evident that the earliest detection of cancers is one of the keys to reducing deaths from these 
diseases and this includes the cancer of the pancreas with its high mortality rates. However, 
effective early diagnosis remains difficult and depends mainly on imaging modalities and 
the development of screening methodologies with highly sensitive and specific biomarkers.
This review summarizes recent advances in effective screening for early diagnosis of 
PDAC using novel molecular biomarkers discovered from various studies including protein 
biomarkers, mutant DNA templates identified in the circulation in blood samples (ctDNA), 
DNA promoter hypermethylation and measurement of microRNA as other possible 
noninvasive biomarker for early detection of Pancreatic Cancer.These data have high translational relevance and suggest that early detection is the key 
issue for improving the prognosis of this aggressive disease. Although many biomarkers for 
early detection of Pancreatic Cancer (PC) have been discovered through various methods, 
effective panels of noninvasive biomarkers for screening and early detection of Pancreatic 
Ductal Adenocarcinoma (PDAC) are not available yet.
The increased number of translational studies would be able to provide this remarkable 
diagnostic tool in a near future. Nevertheless, larger scale and rigorous validation is required 
before their application in the clinic.
IntroductionPancreatic Ductal Adenocarcinoma (PDAC) is the predominant histologic type of 
pancreatic cancer (PC) and has one of the worse prognoses of all types of cancer leading 
to 227,000 deaths annually worldwide. It is currently the fourth leading cause of cancer-
related death in the world. The majority of patients with PC progress to either locally 
advanced or metastatic disease in the asymptomatic phase, as many as 80% presents 
late with metastasis at diagnosis [1]. Metastasis is the most common cause of death in PC 
patients.
Pancreatic Ductal Adenocarcinoma (PDAC) is an infiltrating epithelial neoplasm with glandular (ductal) differentiation, usually demonstrating luminal or intracellular mucin and 
without a predominant component of any other histological type.
Currently, there are three recognized precursors of invasive ductal adenocarcinoma: 
Pancreatic Intraephitelial Neoplasia (PanIN), Intraductal Papillary Mucinous Neoplasm 
(IPMN) and mucinous cystic neoplasm (MCN) (as it is defined in Bosman: WHO Classification 
of Tumours of the Digestive System, 4th Edition, 2010) 
Pancreatic Intraephitelial Neoplasia (PanIN): microscopic papillary or flat, noninvasive epithelial neoplasms that are usually < 5 mm and confined to pancreatic ducts; 
composed of columnar to cuboidal cells with variable mucin and divided into three grades 
according to degree of cytological and architectural atypia which prevalence increases with 
age.
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Intraductal Papillary Mucinous Neoplasm (IPMN): Intraductal 
grossly visible (1 cm or more) epithelial neoplasm of mucin producing 
cells, arising in main pancreatic duct or its branches; neoplastic 
epithelium is usually papillary; variable mucin secretion, duct 
dilatation (cyst formation) and dysplasia; classify based on highest 
degree of cytoarchitectural atypia and invasiveness as: IPMN with 
low to intermediate grade dysplasia; previously called intraductal 
papillary mucinous adenoma, IPMN with high grade dysplasia; 
previously called intraductal papillary mucinous carcinoma, 
noninvasive and IPMN with associated invasive carcinoma.
Mucinous Cystic Neoplasm (MCN): Benign or potentially low 
grade malignant cystic epithelial neoplasm composed of cells which 
contain intracytoplasmic mucin. WHO Classification: with low or 
intermediate grade dysplasia, with high grade dysplasia or with an 
associated invasive carcinoma. Almost always in women, mean age 
45 years, < 20% associated with invasive carcinoma. Metastases 
usually restricted to abdominal cavity; metastases to ovary may 
simulate primary ovarian tumors.Recent advances in effective screening for early diagnosis of 
PDAC using novel molecular biomarkers found in different studies 
have been developed in the last few years. These include different 
kind of methodologies and different molecular targets but the aim of 
all these work is to find noninvasive and highly sensitive and specific 
biomarkers for early detection of Pancreatic Ductal Adenocarcinoma 
(PDAC).
Among the different methods of Cancer diagnosis, we can find 
imaging modalities, protein biomarkers [2], mutant DNA templates 
identified in the circulation (ctDNA) [3], that are derived from 
cancers and their detection in body fluids (feces, urine, pancreatic 
juice samples [4] and saliva. DNA promoter hypermethylation [5] and 
measurement of microRNA as possible noninvasive biomarkers for 
early detection of PC [6,7].
Proposed biomarkers can be found in different body fluids 
mainly in blood and also in urine. It is important to focus in High risk 
population Screening, for identifying early-stage PC and premalignant 
lesions. Several conditions are associated with a high risk of PC and 
these can be classified as hereditary or non-hereditary. Examples 
of common non-hereditary risks are: age (older than 55 years), 
smoking, obesity, alcohol abuse, diabetes, dietary factors, exposure to 
toxic substances and chronic pancreatitis [8].
Regarding Hereditary PC, it has been estimated that ten percent 
of PCs are hereditary. Many of these occur as part of rare medical 
syndromes such as:
Familial breast cancer gene (BRCA2): BRCA2 was the second 
familial breast cancer gene identified. It was discovered in 1995 
because of a remarkable advance made by the Hopkins team studying 
PC. The team at Hopkins had discovered a “homozygous deletion” (a 
missing piece of DNA) in a PC and postulated that this missing piece 
of DNA is where the BRCA2 gene could be found [9]. Subsequently, 
Michael Goggins et al. demonstrated that as many as 10% of PC are 
caused by inherited defects in the BRCA2 gene [10]
Peutz-Jeghers syndrome: This is a very rare hereditary syndrome in which affected family members develop polyps in their 
small intestines and pigmented spots on their lips and inside of 
their mouth. Peutz-Jeghers is caused by inherited mutations in the 
STK11 gene. Patients with this syndrome have a risk of developing 
pancreatic cancer that varies between 7% and 36% by the age of 60 
[11]
Familial melanoma: The Familial Atypical Multiple Mole 
Melanoma (FAMMM) syndrome is a rare hereditary syndrome in 
which affected family members develop skin moles and melanomas 
(an aggressive form of skin cancer). These patients also have an 
increased risk of developing PC. FAMMM is caused by inherited 
mutations in the p16/CDKN2A gene [12,13].
Hereditary colon cancer: The Hereditary Non-Polyposis 
Colorectal Cancer (HNPCC) syndrome, also known as Lynch syndrome, 
strikes as many as 1 in 200 individuals and it is characterized by 
the inherited predisposition to develop colon cancer, endometrial 
(uterine) cancer, stomach cancer and ovarian cancer. Patients with 
HNPCC may also have an increased risk of developing PC. Indeed, the 
DNA finding typical of HNPCC, called microsatellite instability has 
recently been reported in a small (about 4%) fraction of PCs [14].
Hereditary pancreatitis: This rare disease is characterized by 
the development of recurrent episodes of severe chronic pancreatitis 
(inflammation of the pancreas) starting at an early age (often 
in patients in their teens). The gene responsible for hereditary 
pancreatitis, called the trypsinogen gene, was discovered by Dr. 
Whitcomb of the University of Pittsburgh. Clinical gene testing for 
hereditary pancreatitis is now available [15]. Chronic Pancreatitis is 
one of the risk factor for PC. Yachida et al., reported that the time from 
the initiating mutation in the pancreas to development of metastatic 
PC is almost 21 years [16].
Familial PC: While the above genetic syndromes account for 
~20% of familial PC, it is clear that there are other, yet undiscovered 
familial PC genes. For example, relatives of patients with PC have 
an increased risk for developing PC themselves, and the National 
Familial PC Registry now contains over 1500 families in which two or 
more family members have had PC [17]
As we mentioned before, distant metastasis occurs late during 
the genetic evolution of PC. Early detection includes an effective 
screening program, as PC is known to evolve from precursor 
lesions, which can be currently available diagnostic modalities. A 
recent multicenter trial, performed by the International Cancer of 
the Pancreas Screening Consortium (CAPS), CAPS 3 trial, (10) (18) 
demonstrated that screening of asymptomatic individuals at high risk 
for PC frequently detects small cystic pancreatic lesions, including 
curable, noninvasive high-grade neoplasms and that endoscopic 
ultrasound and magnetic resonance imaging were better at detecting 
pancreatic lesions than was computed tomography [19]. We also 
have to take in to account that timely detection of PDAC is masked by 
several factors: lack of specific clinical symptoms in the early stage 
of the disease, insufficient sensitivity of current imaging modalities 
and, despite intensive efforts, lack of accurate body fluid–based 
biomarkers for early detection. Early-stage PDAC is also difficult to 
differentiate from Chronic Pancreatitis (CP), a benign inflammatory 
disease of the pancreas and one of the risk factors for PDAC [20].
Biomarkers in Liquid Biopsies
Biomarkers in Urine
Protein Biomarkers identified in Urine for Early Detection of 
Pancreatic Adenocarcinoma
A panel of three urine biomarkers that can distinguish patients 
with early-stage disease from healthy people, which could enable 
completely noninvasive and inexpensive screening of patients at high 
risk of developing pancreatic adenocarcinoma has been proposed 
(2). Proteins as Biomarkers for Pancreatic Ductal Adenocarcinoma 
has been studied throughout different approaches to find a strategy 
for screening purposes of early stages.
Proteomes of 18 urine samples from healthy controls, chronic 
pancreatitis, and patients with PDAC, (six/group) were assayed 
using GeLC/MS/MS analysis. Three proteins commonly deregulated 
in both males and females (LYVE1, REG1A, and TFF1) were selected 
for further evaluation based in statistical significance and additional 
literature search for previous knowledge on the potential candidates 
as researchers now have access to a new analytics features developed 
to conduct transcriptomic, genomic, mutational as well as integrative 
analyses using publicly available data [21].
LYVE-1
LYVE-1 is a protein codified by Lymphatic Vessel Endothelial 
Hyaluronan Receptor 1. This gene encodes a type I integral 
membrane glycoprotein. The encoded protein acts as a receptor and 
binds to both soluble and immobilized hyaluronan. This protein may 
function in lymphatic hyaluronan transport and have a role in tumor 
metastasis.
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Biomarkers in blood samples
Liquid Biopsy: Circulating tumor DNA and protein 
biomarker-combined for early detection of PCs
ct DNA is DNA circulating that can be found in different body 
fluids. ctDNA coming from dying cancer cells is being targeted. These 
samples of ctDNA can be obtained from body fluids as urine, blood, 
stool, saliva, bile cerebrospinal fluid and pancreatic juice (25, 26, 
27, 28) by means of “liquid biopsies”. Factors released by the tumor 
far microenvironment are decisive for pancreatic adenocarcinoma 
development and progression.
KRAs oncogene, (Kirsten ras oncogene homolog gene), produces 
a small G protein downstream of Epidermal Growth Factor Receptor 
(EGFR). A single amino acid substitution causes an activating 
mutation. Somatic (non-germline) mutations are frequently detected 
in endoderm derived tumors, including colon, lung and pancreas, 
perhaps because activated Kras promotes the expansion of an 
endodermal stem / progenitor cell and blocks its differentiation 
(29,30). The KRAS oncogene, is a potent driver of tumor initiation and 
maintenance. Inactivating mutations in tumor suppressor genes such 
as CDKN2A/p16, TP53, and SMAD4 cooperate with KRAS mutations 
to cause aggressive PDAC tumor growth [31]. Combining ctDNA and 
protein markers increases sensitivity because a large proportion of 
patients are detected by only one marker [32,33].An advantage of using mutant DNA in the circulation as a 
biomarker is its exquisite specificity. Every cell within a cancer has a 
core set of somatic mutations in driver genes that are responsable for 
their clonal growth (34, 35). In contrast, normal cells do not clonally 
expand during adulthood, and the fraction of normal cells that have 
any specific somatic mutation is extremely low.Most studies of Circulating Tumor DNA (ctDNA) have focused 
on following patients with cancer rather than on evaluating its use 
in screening settings. Available data indicate that ctDNA is elevated 
in >85% of patients with advanced forms of many cancer types. 
However, it has been shown that a considerably smaller fraction 
of patients with earlier stages of cancer have detectable levels of 
ctDNA in their plasma [36,37].
ctDNA and protein biomarkers can be combined to increase the 
sensitivity and preserve high specificity under certain conditions. 
Joshua D. Cohen, et al. designed a PCR-based assay that could 
simultaneously assess the two codons (codons 12 and 61) of the 
KRAS gene that are most frequently mutated in PDAC as well as 
surrounding codons (3). Then it is therefore important to determine 
whether the KRAS mutations identified in these patients’ plasma 
samples were also present in their primary carcinomas.
When Primary carcinomas were obtained by surgery from 
patients, KRAS mutations in their plasma were detected in 75.75 % 
of them. In all cases, the mutation found in the plasma was identical 
to that found in the primary carcinoma, this finding provides another 
significant of specificity [38].
Simultaneous Assessment of CA19-9 and KRAS Mutations in 
Plasma were assayed in order to determine whether a combination of 
the KRAS ctDNA test with CA19-9, the best-known PDAC biomarker 
[29], would result in improved sensitivity compared with the KRAS 
ctDNA test alone. It is important to point out that in Lennon AM and 
Goggins M study [29], the samples were obtained only from patients 
with resectable PCs, patients with advanced disease were excluded.
A recent study of Joshua Cohen et al. (3) has shown that CA19-9 
can be elevated in patients with PC, 2 years before diagnosis. However, 
CA19-9 elevations have also been observed, in nonmalignant 
conditions, and 5% of the population cannot produce the CA19-
9 antigen due to germline genetic variation, limiting its use for 
screening purposes. It is important to highlight that whether these 
two biomarkers KRAS mutations and a positive CA19-9 score were 
independent indicators of the presence of disease. However, if the 
threshold for scoring CA19-9 result as positive was sufficiently high it 
might be useful as a screening biomarker. Joshua Cohen et al, (3) used 
a threshold of 100 U/mL based on prior data that this level is not 
REG1A
REG1A also known as islet of Langerhans regenerating protein 
(REG) is a protein that is encoded by the REG1A gene. This protein 
is a type I subclass member of the Regenerating protein family. 
The Reg protein family is a multi-protein family that is involved 
in the proliferation and differentiation of diverse cell types. For 
instance, REG3β is an essential soluble factor necessary for PDAC 
development which is able to stimulate a variety of simultaneous 
pro-tumoral pathways. Also, REG3β suppresses interactions between 
epithelial cells and immune cells by activating a signaling cascade 
mechanism. This mechanism happens to facilitates tumor escape 
through avoiding immune surveillance, and promotes metastasis. 
This protein is expressed and released by the far microenvironment, 
which is situated out of the tumor, at the periphery of the tumor mass, 
and is part of the healthy peri-tumoral region [22].
REG1A protein that is secreted by the exocrine pancreas, is 
associated with islet cell regeneration and diabetogenesis and may 
be involved in pancreatic lithogenesis. Diseases associated with 
REG1A include Pancreatitis and Acinar Cell Carcinoma.
TFF1
TFF1 belongs to a family of gastrointestinal secretory peptides, 
which interact with mucins and are expressed at increased levels 
during reconstitution and repair of mucosal injury. They protect 
epithelial cells from apoptotic death and increase their motility, but 
also play similar pivotal roles in cancer cells, and are thus involved 
in the development and progression of various cancer types. In 
PDAC, TFF1 has been reported in both sporadic and familial PanINs, 
and it has been associated with early stages (I and II) of the disease 
and disease without lymph node involvement, i.e., stage IIA. This 
expression mimics the pattern seen in our urine samples and confirms 
the biologic importance of TFF1 as an early diagnostic biomarker.
Tomasz P. Radon et al, (2) have recently reported high levels of 
the LYVE1, REG1A, and TFF1 in urine samples from patients with 
PDAC. The presence of as full-size proteins in urine specimens was 
confirmed by Western blot and subsequently validated with ELISA 
assays.
When levels of LYVE1 and REG1A were measured after the 
surgery, these biomarkers were significantly decreased. This finding 
also applies to TFF1 regarding a smaller group of patients. This fact 
suggests that the substantial decrease of concentration of these 
biomarkers in urine samples after surgery would be due to the loss of 
tumor mass after the surgery (2).
CA19.9
Cancer antigen 19-9 is used to help differentiate between cancer 
of the pancreas and other conditions, as well as to monitor treatment 
response and recurrence. This antigen is tested in blood samples and 
is used primarily in the management of PC. When analyzing CA19.9 
tumor marker levels were higher in PDACs stage I–II compared with 
pancreatic neuroendocrine tumors (NETs) and duodenal cancer 
samples. When the protein Biomarkers used for detection of early 
stages of PA are combined with CA19.9, accuracy may be increased, 
which may help to understand a recent finding that serum CA19.9 is 
upregulated up to 2 years before PDAC diagnosis [23].
Then a protein Biomarker panel (LYVE1, REG1A, and TFF1) has 
been proposed and a diagnostic test based on urine specimens has 
been developed taking into account that urine is less complex than 
blood and the possibility of obtaining sufficient sample volumes as 
much times as needed in a noninvasive fashion.
It can be pointed out that other of the advantages of urine as a 
sampling method is that this body fluid, constitutes an ultra-filtrate of 
blood, in this way higher concentration of biomarkers can be expected. 
Nevertheless, gender specific differences in protein composition of 
bio fluids were found (24), this should be also analyzed in further 
studies on the subject.
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found among healthy individuals who do not have a clinical history of 
pancreaticobiliary disease.
Regarding this assessment, Joshua Cohen et al, found the 
combined sensitivity of these analysis was significantly higher 
than the sensitivity of either alone. Importantly, the two assays: 
one identifying ctDNA carrying specific Kras mutations associated 
with PC and the other one combining simultaneous assessment of 
CA19-9 and KRAS Mutations in Plasma, could be combined without 
substantially increasing the false-positive rate because each was 
extremely specific at the thresholds used.
Other cell free DNA selected genes Biomarker
DNA Promoter or (O6-alkylguanine DNA alkyltransferase) also 
known as MGMT is a protein that in humans is crucial for genome 
stability. It repairs the naturally occurring mutagenic DNA lesion O6-
methylguanine back to guanine and prevents mismatch and errors 
during DNA replication and transcription. Accordingly, loss of MGMT 
increases the carcinogenic risk in mice after exposure to alkylating 
agents [39].
DNA promoter hypermethylation is a mechanism of early carcinogenesis, which can cause inactivation of tumour 
suppressor genes. The aim of this study was to examine promoter 
hypermethylation in a panel of selected genes from cell-free DNA, as 
a diagnostic marker for pancreatic adenocarcinoma. In patients with 
pancreatic adenocarcinoma, chronic pancreatitis, acute pancreatitis 
and patients screened, but negative for pancreatic adenocarcinoma, 
the difference in mean number of methylated genes in the cancer 
group vs the total control group was highly significant (5).
Cell-free DNA promoter hypermethylation has the potential to be 
a diagnostic marker for pancreatic adenocarcinoma and differentiate 
between malignant and benign pancreatic disease [40,41]. External 
validation is, however, required before the test can be applied in the 
clinic.
Trefoil factor family 2 (TFF2) present in Pancreatic 
Duct Glands, as possible protein biomarker to 
early detection of Intraductal Papillary Mucinous 
NeoplasmsPancreatic Duct Glands (PDGs) are small glands that have 
molecular features known to mark stem cell niches, it is proposed the 
role of PDG as a progenitor niche [42]. These glands are located over 
the main pancreatic ducts that function as progenitor niche for the 
ductal epithelium and they express gastric mucins. Junpei Yamaguchi 
et al. investigated, whether PDGs are a precursor compartment for 
Intraductal Papillary Mucinous Neoplasms (IPMN) a type of neoplasm 
about little is known and the role of trefoil factor family 2 (TFF2), a 
protein expressed by PDGs and the gastric mucosa that are involved 
in epithelial repair and tumor suppression [43].A variety of genetically engineered mouse models of PC have 
been developed over the last decade. PDAC is distinguished by four 
genes that are altered in a very high fraction of patients: the K-ras 
proto-oncogene is mutationally activated in >90% of cases. Given 
the frequency of K-ras mutations in PDAC and their presence in 
the earliest lesions, activation of oncogenic K-ras signaling has 
been proposed to be the primary initiating event in pancreatic 
carcinogenesis [44]. The KC mice model is a genetically model that 
express the KRasG12D oncogene in all pancreatic lineages from early 
embryonic development and incorporates only an activating point 
mutation in Kras that is conditionally expressed in the pancreas. 
Expression of K-rasG12D specifically to the pancreas was targeted 
in this model. Although the mice were born with normal pancreatic 
histology and architecture, an increased pancreatic mass at birth was 
the only difference between double transgenic mice and controls. 
However, by 8 weeks of age, the mice began to develop early lesions 
that slowly increased in both number and grade over the next 2 years. 
A subset of these mice developed pancreatic ductal adenocarcinoma, 
with a median overall survival of 14 months [44]. It is important to 
highlight that the K-rasLSL.G12D/+; PdxCre model (now referred to 
as the KC model) developed a significant background tumor spectrum.
This model provided proof that K-ras mutations are sufficient to 
initiate PC formation in mice [45].
When KC mice, with a genotype that made them able to express 
K-ras mutations and can release protein Tff2 (KC/Tff2+/+) and 
other KC mice with genotype that made them able to express K-ras 
mutations and cannot release protein Tff2 (KC/Tff2−/−), mice 
developed prominent papillary structures in the duct epithelium 
with cystic metaplasia of the PDG, which resembled human IPMN. 
Expression of TFF2 reduced proliferation of PDAC cells 3-fold; this 
effect required upregulation and activation of SMAD4. SMAD4 is 
a gene that codifies a protein that acts as a tumor suppressor and 
inhibits epithelial cell proliferation. It may also have an inhibitory 
effect on tumors by reducing angiogenesis and increasing blood 
vessel hyperpermeability. Loss of TFF2 accelerates tumorization of 
KC mice. Junipei Yamaguchi et al., found expression of TFF2 to be 
down regulated in human PDAC by hypermethylation of its promoter.
According to these findings we can think of TFF2 expression 
as a possible early detection biomarker for Intraductal Papillary 
Mucinous Neoplasms and even though PDAC.
Measurement of microRNA as possible noninvasive 
biomarker for diagnosis of in early detection of PC.
The miRNAs are non-coding RNAs that regulates gene expression 
and have been recognized as deregulated in oncogenesis. miRNAs are 
very stable in blood because they are usually bound to Argonaute, a 
protein that protects them from RNase degradation. Several authors 
reported that miRNAs are deregulated in pancreatic diseases being 
able to discriminate PC from pancreatitis, pancreatic precursor 
lesions and healthy individuals and precursor lesions such as 
Intraductal Papillary Mucinous Neoplasms (IPMN), with malignant 
potential being present in several types of samples [46,47,48].
The miRNAs have been profiled as one of the most popular 
non-invasive biomarker in early detection of PC and numerous of 
these molecules are shown to be deregulated while and after PC 
development. Validations in larger cohorts and consensus regarding 
definitive panels are need before clinical applications would be real 
for patients.
Several miRNAs were identified that exhibited abundance 
variations in both tissue and blood samples. The results could have an immediate diagnostic value for the evaluation of tumor reoccurrence 
in patients, who have undergone curative surgical resection, and for 
people with a familial risk of pancreatic cancer. Several miRNAs were 
found to be associated with tumor-relevant processes. Similar to 
mRNA profiling, miRNA signatures exhibited distinctive expression 
variations in pancreatic tumor samples, chronic pancreatitis tissue 
and normal pancreas. The transcripts miR-21, miR-155, miR-203, 
miR-210 and miR-222 were described as potential predictors of 
survival. However, the tissue-based miRNA studies also suffer from the fact that invasive action is required to acquire material for 
analysis, and as such, tissue-based miRNA profiling does not offer 
significant progress compared to messenger RNA profiling but for the 
superior stability of miRNA.
Markers that occur in peripheral blood or other body fluids would 
be best for detection. For various tumor entities, extracellular nucleic 
acids have been found in serum. In part, they have their origin in 
circulating tumor cells. Moreover, the actual tumor cells themselves 
could be isolated from blood and used as a means for diagnosis and 
prognosis.
Conclusion
Pancreatic cancer survival time has a strong correlation between 
tumor stage and prognosis. Performing High Risk population 
screening, by means of Biomarkers in liquid biopsies, would lead us 
to remarkable achievements in the subject. As shown in Figure 1.
In this article, we have reviewed biomarkers in urine and 
biomarkers in blood.
Three urine protein biomarkers, noninvasive inexpensive that 
can distinguish patients with early-stage/ healthy people/high risk 
of developing PDAC: LYVE1, REG1A, and TFF1. The levels of these 
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three biomarkers in urine samples from patients with PDAC, where 
significantly higher. In patients for whom samples were collected 
before and after surgery, levels of LYVE1 and REG1A and also TFF1 
decrease likely due to substantial loss of tumor mass after surgery. 
Combination of protein biomarker panel in urine, plus protein 
biomarkers as C19.9 in plasma samples would improve detection on 
early stages of Pancreatic Cancer.
Nevertheless, biomarkers in blood are also liquid biopsies as 
circulating tumor, (ctDNA), released by dying cancer cells than can 
escape into body fluids such as urine, blood, stool and pancreatic 
juice. In this review, we pointed out that mutant DNA circulating in 
Blood is an exquisite marker in terms of specificity as it is elevated 
in › 85% of patients with advanced forms of many cancer types. 
Combination of ctDNA and Protein Biomarkers as C19.9, compared 
in certain conditions would improve detection on early stages of 
Pancreatic Cancer.
Another two useful biomarkers in blood would be measurement 
of microRNA (miRNAs) and DNA promoter hypermethylation.
MicroRNA have been profiled as one of the most popular non-
invasive biomarker in early detection of PC. These molecules are non-
coding RNAs very stable in blood, that regulates gene expression and 
have been recognized as deregulated in oncogenesis. In pancreatic 
diseases, they can discriminate PC from pancreatitis, healthy 
individuals and pancreatic precursor lesions such as Intraductal 
Papillary Mucinous Neoplasms (IPMN), with malignant potential.
DNA promoter hypermethylation is a mechanism of early 
carcinogenesis. DNA Promoter, also known as MGMT, repairs the 
naturally occurring mutagenic DNA lesions and prevents mismatch 
lesions and errors during DNA replication and transcription. Cell-free 
DNA promoter hypermethylation has the potential to be a diagnostic 
Figure 1
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marker for pancreatic adenocarcinoma and differentiate between 
malignant and benign pancreatic disease.
On the other hand, possible use of protein factors as Trefoil 
Factor Family2 (TFF2) present in Pancreatic Duct Glands (PDGs) 
as biomarker to early detection of Intraductal Papillary Mucinous 
Neoplasms (IPMN). The role of Trefoil Factor Family 2 (TFF2), a 
protein expressed by PDGs and the gastric mucosa that is to be 
involved in epithelial repair and tumor suppression. KC mice model 
as was described above, provided proof that K-ras mutations are 
sufficient to initiate pancreatic cancer formation in mice. Loss of 
TFF2 accelerates tumorization of KC mice and expression of TFF2 
to be down regulated in human PDAC by hypermethylation of its 
promoter. Then we can think of TFF2 expression as a possible early 
detection biomarker for Intraductal Papillary Mucinous Neoplasms 
and even though PDAC.
Based on data provided in the items commented above we can 
conclude that assays for genetic alterations can be combined with 
assays for elevated proteins to increase the sensitivity of a blood test 
for low-stage pancreatic cancer.
Larger scale and rigorous validation is required before their 
application in the clinic. In addition, more effective and specific 
biomarkers of PDAC and PDAC pathogenesis at the genetic and 
molecular level, as well as novel therapeutic opportunities to treat 
this highly aggressive disease are urgently needed. Fortunately, as 
it was mentioned above, the increased number and importance 
of Translational studies in the subject, would lead us to achieve 
this remarkable tool in a near future. A novel method combining 
Protein biomarkers and in urine and the challenge of identifying, 
(ctDNA) mutant DNA templates in urine could lead us to a less 
complex, method that provides a stable matrix for analysis, and can 
be repeatedly and noninvasively sampled in sufficient volumes.
A useful biomarker with applicability for early diagnosis 
should be minimally or non-invasive and have high sensitivity, high 
specificity and capacity to discriminate low-grade dysplasia from 
high-grade dysplasia and cancer.
Minimally-invasive or non-invasive biomarkers are required to 
encourage use for clinicians and compliance in patients. Only non-
invasive tests are practical enough and will be able to maximize 
access. To obtain these properties, biomarkers in blood, urine, saliva, 
feces or pancreatic juice samples must be more deeply investigated.
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